Norgestrel
- Generic Name
- Norgestrel
- Brand Names
- Cryselle 28, Elinest 28 Day, Lo/ovral 28 Day, Low-ogestrel 28 Day, Turqoz 28 Day
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28O2
- CAS Number
- 6533-00-2
- Unique Ingredient Identifier
- 3J8Q1747Z2
- Background
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active.
- Indication
Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
- Associated Conditions
- Abnormal Uterine Bleeding, Endometriosis, Hypermenorrhea, Menstrual Distress (Dysmenorrhea), Polycystic Ovarian Syndrome (PCOS)
- Associated Therapies
- Emergency Contraception, Oral Contraceptives
Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
Phase 2
Completed
- Conditions
- Endometrial Cancer
- Interventions
- Drug: medroxyprogesteroneDrug: ethinyl estradiolOther: laboratory biomarker analysisDrug: norgestrel
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00033358
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath